

1617

PTO/SB/21 (03-03)

Approved for use through 04/30/2003. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

|  |                    |                        |          |
|--|--------------------|------------------------|----------|
| Application Number                       | 10/056,680         |                        |          |
| Filing Date                              | 01/25/2002         |                        |          |
| First Named Inventor                     | T. Kosoglou et al. |                        |          |
| Art Unit                                 | 1617               |                        |          |
| Examiner Name                            | Mojdeh Bahar       |                        |          |
| Total Number of Pages in This Submission | 5                  | Attorney Docket Number | CV01492K |

**ENCLOSURES (Check all that apply)**

|   |  |  |
|---|--|--|
| <input type="checkbox"/> Fee Transmittal Form<br><input type="checkbox"/> Fee Attached<br><input type="checkbox"/> Amendment/Reply<br><input type="checkbox"/> After Final<br><input type="checkbox"/> Affidavits/declaration(s)<br><input type="checkbox"/> Extension of Time Request<br><input type="checkbox"/> Express Abandonment Request<br><input checked="" type="checkbox"/> Information Disclosure Statement<br><input type="checkbox"/> Certified Copy of Priority Document(s)<br><input type="checkbox"/> Response to Missing Parts/ Incomplete Application<br><input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53 | <input type="checkbox"/> Drawing(s)<br><input type="checkbox"/> Licensing-related Papers<br><input type="checkbox"/> Petition<br><input type="checkbox"/> Petition to Convert to a Provisional Application<br><input type="checkbox"/> Power of Attorney, Revocation<br><input type="checkbox"/> Change of Correspondence Address<br><input type="checkbox"/> Terminal Disclaimer<br><input type="checkbox"/> Request for Refund<br><input type="checkbox"/> CD, Number of CD(s) _____ | <input type="checkbox"/> After Allowance Communication to Group<br><input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences<br><input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)<br><input type="checkbox"/> Proprietary Information<br><input type="checkbox"/> Status Letter<br><input checked="" type="checkbox"/> Other Enclosure(s) (please Identify below):<br>Certificate of Mailing PTO/SB92 - 1 Page<br>PTO-1449 - 1 Pg. in dup.; (15) References |
| Remarks   |  |  |

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

|                    |   |
|--------------------|---|
| Firm or Individual | Ann Marie Cannon, Reg. No. 35,972   |
| Signature          |  |
| Date               | 11/25/2003  |

**CERTIFICATE OF TRANSMISSION/MAILING**

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: \_\_\_\_\_

|                  |      |  |
|------------------|------|--|
| Typed or printed |      |  |
| Signature        | Date |  |

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Application No.: 10/056,680

Filing Date: 01/25/2002

Applicant: T. Kosoglou et al.

Title: Combinations of Sterol Absorption Inhibitor(s) with Blood Modifier(s) for Treating Vascular Indications

**Certificate of Mailing under 37 CFR 1.8**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

on 11/25/2003

Date

  
SignatureAnn Marie Cannon, Reg. No. 35,972

Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Documents enclosed:

Response Transmittal PTO/SB/21 - 1 Page  
Information Disclosure Statement - 1 Page  
PTO-1449 - 1 Pg. in dup.; (15) References  
Certificate of Mailing PTO/SB92 - 1 Page  
Post Card

This collection of information is required by 37 CFR 1.8. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.8 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PATENT CASE CV01492K

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:  
**T. Kosoglou et al.**

For: **Combinations of Sterol Absorption  
Inhibitor(s) with Blood Modifier(s)  
for Treating Vascular Indications**

Serial No.: **10/056,680**

Filed: **01/25/2002**

X : Examiner: **Mojdeh Bahar**

: Group Art Unit: **1617**

: Date: **November 25, 2003**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Schering-Plough Corporation  
Kenilworth, New Jersey 07033-0530

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT


Sir:

It is requested that the documents listed on the accompanying PTO-1449 Form be considered and made of record in the above-identified patent application. A copy of each cited document is attached.

No fee is believed to be due, however, if any fee is due the Commissioner is authorized to charge **Deposit Account Number 19-0365** for any fees deemed necessary for consideration and entry of this Information Disclosure Statement into the file record.

Respectfully submitted,

SCHERING-PLOUGH CORPORATION

  
Ann Marie Cannon  
Reg. No., 35,972  
Attorney for Applicants  
(908) 298-5024



Sheet 1 of 1

|  |  |  |  |   |                                       |
|--|--|--|--|---|---------------------------------------|
| FORM PTO-1449  |  | U.S. DEPARTMENT OF COMMERCE<br>PATENT AND TRADEMARK OFFICE |  | ATTY. DOCKET NO.:<br><b>CV01492K</b>    | APPLICATION NO.:<br><b>10/056,680</b> |
| INFORMATION DISCLOSURE STATEMENT<br>BY APPLICANT<br><i>(Use several sheets if necessary)</i> |  |  |  | APPLICANT:<br><b>T. Kosoglou et al.</b> |                                       |
|  |  |  |  | FILING DATE:<br><b>01/25/2002</b>       | GROUP:<br><b>1617</b>                 |

#### U.S. PATENT DOCUMENTS

| *EXAMINER INITIAL | DOCUMENT NUMBER | DATE     | NAME          | CLASS | SUB-CLASS | FILING DATE IF APPROPRIATE |
|-------------------|-----------------|----------|---------------|-------|-----------|----------------------------|
| AA                | 6,030,990       | 02/29/00 | Maeda et al.  |       |           |                            |
| AB                | 6,166,049       | 12/26/00 | Smith et al.  |       |           |                            |
| AC                | 2003/0153541    | 08/14/03 | Dudley et al. |       |           |                            |
|                   |                 |          |               |       |           |                            |
|                   |                 |          |               |       |           |                            |
|                   |                 |          |               |       |           |                            |
|                   |                 |          |               |       |           |                            |

#### FOREIGN PATENT DOCUMENTS

|    | DOCUMENT NUMBER | DATE     | COUNTRY | CLASS | SUB-CLASS | TRANSLATION |
|----|-----------------|----------|---------|-------|-----------|-------------|
|    |                 |          |         |       |           | YES         |
| AD | WO 01/14351     | 03/01/01 | PCT     |       |           |             |
| AE | WO 01/34148     | 05/17/01 | PCT     |       |           |             |
| AF | WO 01/60807     | 08/23/01 | PCT     |       |           |             |
| AG | WO 02/064094    | 08/22/02 | PCT     |       |           |             |
| AH | WO 02/08188     | 01/31/02 | PCT     |       |           |             |
| AI | WO 02/26729     | 04/04/02 | PCT     |       |           |             |
| AJ | WO 03/039542    | 05/15/03 | PCT     |       |           |             |
| AJ | WO 03/074101    | 09/12/03 | PCT     |       |           |             |
| AL | WO 03/088962    | 10/30/03 | PCT     |       |           |             |
|    |                 |          |         |       |           |             |
|    |                 |          |         |       |           |             |
|    |                 |          |         |       |           |             |
|    |                 |          |         |       |           |             |

#### OTHER DOCUMENTS (*Including Author, Title, Date, Pertinent Pages, Etc.*)

|    |  |
|----|--|
| AM | Sorbera et al., Netoglitazone, <i>Drugs of the Future</i> , 2002, 27(2): 132-139   |
| AN | Michel Farnier, Nouvelles approches médicamenteuses dans le traitement des dyslipidémies, <i>MT Endocrinologie</i> , 2002, 4:252-259                               |
| AO | Berger et al., Physiological and Therapeutic Roles of Peroxisome Proliferator-Activated Receptors, <i>Diabetes Technology &amp; Therapeutics</i> , 2002, 4:163-174 |
|    |  |
|    |  |
|    |  |
|    |  |

| EXAMINER | DATE CONSIDERED |
|----------|-----------------|
|          |                 |

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



# DUPLICATE

Sheet 1 of 1

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.:  
**CV01492K**

APPLICATION NO.:  
**10/056,680**

APPLICANT:  
**T. K. soglou et al.**

FILING DATE:  
**01/25/2002**

GROUP:  
**1617**

### U.S. PATENT DOCUMENTS

| *EXAMINER INITIAL | DOCUMENT NUMBER | DATE     | NAME          | CLASS | SUB-CLASS | FILING DATE IF APPROPRIATE |
|-------------------|-----------------|----------|---------------|-------|-----------|----------------------------|
| AA                | 6,030,990       | 02/29/00 | Maeda et al.  |       |           |                            |
| AB                | 6,166,049       | 12/26/00 | Smith et al.  |       |           |                            |
| AC                | 2003/0153541    | 08/14/03 | Dudley et al. |       |           |                            |
|                   |                 |          |               |       |           |                            |
|                   |                 |          |               |       |           |                            |
|                   |                 |          |               |       |           |                            |

### FOREIGN PATENT DOCUMENTS

|    | DOCUMENT NUMBER | DATE     | COUNTRY | CLASS | SUB-CLASS | TRANSLATION | YES | NO |
|----|-----------------|----------|---------|-------|-----------|-------------|-----|----|
| AD | WO 01/14351     | 03/01/01 | PCT     |       |           |             |     |    |
| AE | WO 01/34148     | 05/17/01 | PCT     |       |           |             |     |    |
| AF | WO 01/60807     | 08/23/01 | PCT     |       |           |             |     |    |
| AG | WO 02/064094    | 08/22/02 | PCT     |       |           |             |     |    |
| AH | WO 02/08188     | 01/31/02 | PCT     |       |           |             |     |    |
| AI | WO 02/26729     | 04/04/02 | PCT     |       |           |             |     |    |
| AJ | WO 03/039542    | 05/15/03 | PCT     |       |           |             |     |    |
| AJ | WO 03/074101    | 09/12/03 | PCT     |       |           |             |     |    |
| AL | WO 03/088962    | 10/30/03 | PCT     |       |           |             |     |    |
|    |                 |          |         |       |           |             |     |    |
|    |                 |          |         |       |           |             |     |    |
|    |                 |          |         |       |           |             |     |    |

### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

|    |  |
|----|--|
| AM | Sorbera et al., Netoglitazone, <i>Drugs of the Future</i> , 2002, 27(2): 132-139   |
| AN | Michel Farnier, Nouvelles approches médicamenteuses dans le traitement des dyslipidémies, <i>MT Endocrinologie</i> , 2002, 4:252-259                               |
| AO | Berger et al., Physiological and Therapeutic Roles of Peroxisome Proliferator-Activated Receptors, <i>Diabetes Technology &amp; Therapeutics</i> , 2002, 4:163-174 |
|    |  |
|    |  |
|    |  |

|          |                 |
|----------|-----------------|
| EXAMINER | DATE CONSIDERED |
|----------|-----------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.